Is now the time to buy Cochlear?

With the share price down 15% since the start of the year, is this the opportunity investors have been waiting for?

a woman

You鈥檙e reading a free article with opinions that may differ from The Motley Fool鈥檚 Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Hearing implant manufacturer Cochlear Limited (ASX: COH) has seen its share price fall 3% today to $66.03, despite no news to explain the fall. Shareholders may have become a little more than exasperated by the recent share price action, including a 4% rise last week, a 9% fall on Feb 5 2012, a 4% fall the day after, and a 3% fall on February 21.

The big fall of around 13% at the start of February appears mainly due to the company narrowly missing analyst estimates of an $80 million half year profit. To recap, Cochlear reported a net profit of $77.7 million for the six months to December 2012, recovering from a $20 million loss the year prior, on the back of a recall of its flagship CI500 series hearing implant in September 2011.

Cochlear was forced to re-start manufacturing of its previous model implant, which from all reports is still superior to many of its competitor鈥檚 products. Cochlear has yet to confirm when its flagship CI500 implant will be reintroduced, although it鈥檚 possible that the company will instead release a newer, improved model to replace both the CI500 and its temporary replacement models.

In the meantime, a number of low cost competitors have sprung up, seeking to take advantage of Cochlear鈥檚 high prices it charges for its implants. Yesterday, the China Digital Times reported that Hangzhou Nurotron Biotechnology, has received approval to sell its implant in mainland China at around less than half the costs of its major competitors products, including Cochlear, and expects to eventually seek US Food and Drug Administration approval for its devices.

In India, government-backed researchers are starting clinical trials of a locally developed device, with expectations that if the two year trials go according to plan, a made-in-India implant could cost as little as US$2,500.

So along with its existing competitors, Sonoma and Advanced Bionics, Cochlear also faces up and coming competition from companies that have comparatively very low costs of production. On face value that might be enough for shareholders to abandon Cochlear. But Cochlear has the advantage of refining its products over many years, and has built up a strong competitive advantage, leading to its virtual monopoly in cochlear implants. That competitive advantage should not be underestimated.

Its junior competitors in China and India don鈥檛 have that history and arguably their products may not be as well designed as Cochlear鈥檚 implants and accessories. As Cochlear鈥檚 competitor Sonoma found, one small issue is enough to see a product recalled, which ruins the company鈥檚 reputation and makes it incredibly hard for customers to trust it again.

There鈥檚 also another factor that will likely work in Cochlear鈥檚 favour as well as its competitors. China has an estimated 28 million deaf people, while 30,000 Chinese babies are born without hearing each year. That is a huge virtually untapped market, and the rise in the awareness of cochlear treatments could see a rise in the sale of cochlear implants for all providers as the market expands.

Foolish takeaway

With a virtually unblemished record for many years, apart from the 2011 recall, investors should not rule out Cochlear maintaining its dominance of the market, as well as聽benefiting from the increased awareness of cochlear implants in the world鈥檚 largest populated countries. Should the price drop much from here, I鈥檒l be looking to top up my holding.

With its legendary, fully franked 28 cent dividend, Telstra is the darling of Aussie investors. Chances are even if you don’t own Telstra shares directly, your superannuation fund does. But with its share price skyrocketing over the past year, is Telstra past its prime?聽Click here聽for our brand-new report:聽Buy, Sell, or Hold Telstra?

More reading

The Motley Fool鈥檚 purpose is to help the world invest, better.聽Click here now聽for your free subscription to Take Stock, The Motley Fool鈥檚 free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead.聽 This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. Motley Fool writer/analyst Mike King owns shares in Cochlear.

More on 鈴革笍 Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more

woman holds sign saying 'we need change' at climate change protest

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
鈴革笍 Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
鈴革笍 Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more

asx share price competitions represented by businessmen arm wrestling
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more

asx investor daydreaming about US shares
鈴革笍 How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more

person reading news on mobile phone
鈴革笍 Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more